Stem cell therapy for autoimmune disease

01Overview and value chain

Markers: [EC: ATMP Regulation (EC No 1394/2007) + FDA cell-therapy guidance | OECD: Bio-pharma | Regulator: FDA (USA), EMA (European Union), NMPA (China)]

Stem cell therapy for autoimmune disease uses living cells — mesenchymal stromal cells (MSC) or regulatory T cells (Treg) — to re-tolerise rather than suppress the immune system, addressing lupus, Crohn’s, arthritis, GVHD and aplastic anaemia. Mesoblast’s Ryoncil (remestemcel-L) saw the FDA accept its Biologics License Application for paediatric steroid-refractory acute graft-versus-host disease; TiGenix (a Takeda company) provides Alofisel (darvadstrocel) for Crohn’s disease perianal fistulas; Cellenkos received FDA clearance for a Phase 2 trial of CK0801 (allogeneic cord-blood Treg) in aplastic anaemia; Sonoma Biotherapeutics is advancing an engineered-Treg pipeline in autoimmune disease; and GentiBio presented preclinical data for GNTI-122, an autologous antigen-specific engineered Treg.

The key directions of stem cell therapy for autoimmune disease are:

1. Mesenchymal stromal cell therapy (MSC): allogeneic MSC immunomodulation for inflammatory disease — Mesoblast (remestemcel-L/Ryoncil, steroid-refractory acute GVHD), TiGenix (darvadstrocel/Alofisel, Crohn’s perianal fistula).
2. Regulatory T-cell therapy (Treg): polyclonal or antigen-specific Treg infusion to restore tolerance — Cellenkos (CK0801 cord-blood Treg, aplastic anaemia), Sonoma Biotherapeutics (engineered Treg), GentiBio (GNTI-122 antigen-specific Treg).
3. Haematopoietic stem-cell reset (HSCT): autologous HSCT for severe refractory autoimmune disease (lupus, MS), a clinical-procedure rather than product-led approach.
4. Allogeneic off-the-shelf manufacturing (Allogeneic Manufacturing): donor-derived MSC and Treg banking that supports repeat-dose, inventory-managed cell therapy.

Sectoral value chain

[donor MSC / cord-blood Treg / patient Treg] ──> [ex vivo activation, engineering & expansion] ──> [cryopreserved cell product]
                                              │
                                     (conditioning as needed)
                                              │
                                              ▼
[immune tolerance restored] <─── [cell infusion + immune monitoring] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• MSC immunomodulation (MSC): allogeneic MSC suppress inflammation via IDO, PGE2 and T-cell modulation, enabling off-the-shelf use across HLA barriers (Mesoblast, TiGenix).
• Treg stability and specificity (Treg): maintaining FOXP3 expression and engineering antigen-specific TCRs so the infused Treg homes to the diseased tissue (Cellenkos, Sonoma, GentiBio).
• Allogeneic off-the-shelf banking (Allogeneic Manufacturing): donor-derived MSC/Treg banked as inventory distinguishes this class from autologous cell therapy.

02US

The US hosts Mesoblast (the MSC commercial leader), Cellenkos, Sonoma Biotherapeutics and GentiBio, and the FDA has accepted the lead MSC asset’s BLA.

Mesoblast, Cellenkos, Sonoma, GentiBio, FDA

• Mesoblast: the FDA accepted its Biologics License Application for Ryoncil (remestemcel-L) in children with steroid-refractory acute graft-versus-host disease, the lead allogeneic-MSC regulatory asset; remestemcel-L is the most-studied MSC in inflammatory disease.
• Cellenkos: received FDA clearance to initiate a Phase 2 clinical trial of CK0801, an allogeneic cord-blood-derived Treg, for aplastic anaemia, extending Treg therapy beyond oncology into autoimmune haematology.
• Sonoma Biotherapeutics: a clinical-stage biotechnology company advancing an engineered-Treg pipeline for autoimmune disease, presenting data at the 2025 ACR meeting.
• GentiBio: presented preclinical data for GNTI-122, its autologous antigen-specific engineered Treg lead, an approach designed to restore tolerance with tissue-restricted specificity.
• FDA framework: MSC and Treg products are reviewed as advanced therapy biologics with cell-therapy-specific CMC, potency (often IDO for MSC) and long-term follow-up expectations.

03CN

China runs an active academic-MSC autoimmune programme, with MSC clinical use in lupus and other autoimmune diseases, though it is more research- than product-led.

academic MSC, lupus, NMPA

• Academic MSC in lupus: Chinese centres have published extensively on MSC immunosuppression in systemic lupus erythematosus (e.g. effects on dendritic cells), but enrichment returned academic literature rather than a source-confirmed commercial MSC/Treg product, so the CN block is treated qualitatively.
• NMPA framework: cell-therapy products are reviewed under the NMPA biologics framework; several MSC products are in domestic clinical use, but a dominant branded autoimmune MSC/Treg has not emerged.
• Autoimmune burden: China’s large systemic-autoimmune disease burden underpins sustained clinical interest in MSC and Treg tolerance therapy.

04EU

Europe contributed the EU-approved MSC product Alofisel (TiGenix/Takeda) and the EMA’s central ATMP authorisation route.

TiGenix, Takeda, EMA, ATMP

• TiGenix (Spain, a Takeda company): its Alofisel (darvadstrocel) is an EU-approved allogeneic MSC for complex perianal fistulas in adult Crohn’s disease, and Takeda provides periodic updates on the programme as the EU’s lead commercial autoimmune-MSC asset.
• EMA framework: stem-cell products are advanced therapy medicinal products centrally authorised by the European Medicines Agency under Regulation (EC) No 1394/2007, with the hospital-exemption carve-out used cautiously for autologous products.
• European CDMO: European cell-therapy CDMOs support GMP MSC expansion and cryopreservation, underpinning the allogeneic-bank model.

05Leading companies and research institutes

06Tech stack and innovations

The stack pairs MSC or Treg cell sourcing with ex vivo expansion (and Treg engineering), allogeneic GMP banking, and immune-tolerance monitoring.

1. Mesenchymal stromal cell therapy (MSC):
   • Mesoblast’s Ryoncil (remestemcel-L) had its BLA accepted for paediatric steroid-refractory acute GVHD, and TiGenix’s Alofisel (darvadstrocel) is EU-approved for Crohn’s perianal fistula — the two lead commercial autoimmune/inflammatory MSC assets.
   • Allogeneic MSC act via IDO/PGE2 immunomodulation across HLA barriers, enabling off-the-shelf use.
2. Regulatory T-cell therapy (Treg):
   • Cellenkos’s CK0801 (allogeneic cord-blood Treg) entered Phase 2 in aplastic anaemia; Sonoma Biotherapeutics is clinical-stage in engineered Treg for autoimmune disease, and GentiBio presented preclinical data for GNTI-122, an antigen-specific engineered Treg.
   • Maintaining FOXP3 stability and engineering tissue-specific TCRs is what converts polyclonal Treg into disease-targeted tolerance therapy.
3. Allogeneic manufacturing (Allogeneic Manufacturing):
   • Donor-derived MSC and cord-blood Treg are banked as inventory, a structural shift from autologous cell therapy toward repeat-dose off-the-shelf cell drugs.

07Value chains and production pipelines

Industrial pipeline of an autoimmune MSC/Treg product (ATMP Regulation)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Cell source & donor    │ ───> │ 2. Engineering &          │
└───────────────────────────┘      │    expansion             │
                                   └───────────────────────────┘
                                                   │
                                                   ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Patient conditioning   │ <─── │ 3. GMP manufacture &      │
│                           │      │    banking                │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Infusion & monitoring  │ ───> │ 6. Follow-up & PV         │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Cell source and donor

Starting cells are sourced — donor bone-marrow/umbilical-cord MSC (Mesoblast, TiGenix), cord-blood Treg (Cellenkos), or autologous patient Treg (GentiBio) — with donor screening and HLA matching considered per product.

Stage 2: Engineering and expansion

MSC are expanded to therapeutic dose in culture; Treg are activated and expanded, and where antigen-specific, engineered with a tissue-homing TCR or CAR (Sonoma, GentiBio) before release testing.

Stage 3: GMP manufacture and banking

Allogeneic MSC and Treg are fill-finished, cryopreserved and banked as inventory under GMP, supporting off-the-shelf repeat-dose use; potency assays (e.g. IDO for MSC, FOXP3 for Treg) are the central release challenge.

Stage 4: Patient conditioning

MSC require minimal conditioning; some Treg protocols use low-dose lymphodepletion or IL-2 support to favour in-vivo Treg expansion and persistence.

Stage 5: Infusion and monitoring

The cell product is infused and the patient is monitored for tolerance induction (disease response, biomarker shifts) and acute infusion reactions.

Stage 6: Follow-up and pharmacovigilance

Long-term follow-up tracks durability of tolerance, need for repeat dosing, and safety (including any loss of tolerance or ectopic tissue effects), feeding the pharmacovigilance record for this still-young autoimmune cell-therapy class.